A 45% increase in global revenues, an expanded client base and new contracts with 11 of the world’s top 25 pharmaceutical companies helped make 2009 “the best financial year yet” for ClinTec, the company said.

According to Dr Rabinder Buttar, founder, president and chief executive officer of the contract research organisation (CRO) based in Glasgow, Scotland, ClinTec is “at the top of its growth metrics when compared to competitors”. Current projections suggest growth in 2010 and 2011 will be “sustained to the same high levels”, he added.

In a difficult economic climate that has seen other CROs hit by project delays and cancellations, ClinTec “forged ahead developing innovative services in 17 new countries, employing 115 new staff in the process”, Buttar noted.

The company now has a presence in some 40 countries around the world, covering Western Europe, Central and Eastern Europe, the Middle East and North Africa, Central and South Africa, Latin America, India and the US. It manages clinical trials in all the major therapeutic areas, including oncology, neurology and gastroenterology as well as cardiovascular and respiratory diseases.

ClinTec further highlighted the launch last October of its office in Cairo, Egypt. This not only gives clients access to new patient populations but “cements our reputation as the major CRO in the Middle East and North Africa region”, Buttar commented.

It also helps to facilitate the complex restructuring programmes undertaken by pharmaceutical multinationals as they look for innovative ways to optimise their research and development efforts, ClinTec observed.

“The shift of research delivery from West to East is an area in which ClinTec is clearly able to offer a credible solution for using a blend between flexible resource solutions and off-shore project delivery,” it stated.